Faeth Therapeutics (FTH) Interest Expenses (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Interest Expenses came in at $12.2 million in Q1 2026, up 2453.36% YoY from $476000.0 in Q1 2025, and up 1043.63% on a QoQ basis from -$1.3 million in Q4 2025.
Faeth Therapeutics (FTH) Interest Expenses (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Interest Expenses data on file, last reported at $12.2 million in Q1 2026.
- Quarterly Interest Expenses rose 2453.36% year-over-year to $12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (up 364.07% YoY) and the FY2025 annual result came in at $60.8 million, up 4.5% from the prior year.
- Interest Expenses grew to $12.2 million in Q1 2026, from -$1.3 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $12.2 million in Q1 2026 to a low of -$1.3 million in Q4 2025.
- A 5-year average of $2.2 million and a median of $1.7 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2025 — Interest Expenses tumbled 7676.47% — and 2026, when it soared 2453.36%.
- Tracing FTH's Interest Expenses over 5 years: stood at -$206000.0 in 2022, then jumped by 907.77% to $1.7 million in 2023, then plunged by 98.98% to $17000.0 in 2024, then plunged by 7676.47% to -$1.3 million in 2025, then surged by 1043.63% to $12.2 million in 2026.
- The last three Interest Expenses figures came in at $12.2 million (Q1 2026), -$1.3 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Faeth Therapeutics | 180.89 Mn | 180.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.48 Mn |
| Jun 30, 2026 | 6.48 Mn |
| Mar 31, 2026 | 12.15 Mn |
| Mar 31, 2026 | 12.15 Mn |
| Dec 31, 2025 | -1.29 Mn |
| Dec 31, 2025 | -1.29 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 476,000.00 |
| Mar 31, 2025 | 476,000.00 |
| Dec 31, 2024 | 17,000.00 |
| Dec 31, 2024 | 17,000.00 |
| Sep 30, 2024 | 3.70 Mn |
| Sep 30, 2024 | 3.70 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 462,000.00 |
| Mar 31, 2024 | 462,000.00 |